MISSISSAUGA, ON, Nov. 3, 2014 /CNW/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it plans to commence a Phase 3 clinical study of Pennsaid 2% for the treatment of acute pain to support regulatory approval applications for Pennsaid 2% in international jurisdictions. The study will be conducted in Germany to assess the efficacy of Pennsaid 2% for the relief of pain associated with acute, localized muscle or joint injuries such as sprains, strains or sports injuries. Commencement of the study, which is subject to German regulatory approval, is expected in Q2 2015 with top-line results expected Q4 2015. The study will cost approximately CDN$1.5 million.
Nuvo Research® Sells PENNSAID® 2% U.S. Rights for US$45 Million to Horizon Pharma
MISSISSAUGA, ON, Oct. 17, 2014 /CNW/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has completed the sale of its PENNSAID 2% U.S. sales and marketing rights to Horizon Pharma plc (NASDAQ:HZNP) for a cash payment ofUS$45 million (CDN$50 million) which was payable on closing.
Please click here to view the full press release.
iWallet Appoints Three New Members to Its Board of Directors
SAN DIEGO, CA–(Marketwired – October 08, 2014) – iWallet Corporation (OTCQB: IWAL), the secure luxury techcessories company, announced it has appointed three new members to its board of directors including Carl Rosen, former COO of Bulova, then international consumer luxury goods company; Charles Ng, VP of sales at NEXT Biometrics and the former North American director of sales for Fingerprint Cards and sales director for Authentec, a biometric fingerprint technology; and Anthony Durkacz, EVP of the investment firm First Republic Capital Corporation.
Virtutone Announces Earnings of $0.02 per share for period ended July 31, 2014
Sherwood Park, Alberta / TNW-ACCESSWIRE / September 30, 2014 / Virtutone Networks Inc. (“Virtutone” or the “Company”) (TSX Venture: VFX.V) is pleased to announce its financial results for the three and six -month period ended July 31, 2014.
Alabama Graphite Reports 54.7% Large and Jumbo Flake Graphite with Purities Ranging from 96.3% to 98.5% at its Bama Property
Alabama Graphite Corp. (“Alabama Graphite” or the “Company”) (ALP) (otcqx:ABGPF) (frankfurt:1AG WKN) (ISIN# CA0102931080) is pleased to announce that it has received the first set of metallurgical results from SGS Laboratory in Lakefield, Ontario, Canada on sample material originating from the newly acquired Bama Property. Using only simple floatation (without chemical or thermal treatment) the Bama composite sample produced a graphite concentrate that contained an aggregate of 54.7% large flake (+80 mesh), of which 17.8% was in the jumbo flake (+48 mesh) category. For all size ranges coarser than +150 mesh the purity exceeded 96.3% with the jumbo flake fraction having a purity of 98.5% in Scoping Level Evaluations.
Alabama Graphite Acquires Prior Producing Bama Flake Graphite Mine in Chilton County, Alabama, USA
Vancouver, BC / TNW-ACCESSWIRE / September 18, 2014 / Alabama Graphite Corp. (the “Company”) (TSX-V:ALP) (OTCQX:ABGPF) (FRANKFURT: 1AG WKN: A1J35M) (ISIN# CA0102931080) is pleased to announce that it has entered into a mineral lease on a land package that includes the prior producing Bama flake graphite Mine in Chilton County, Alabama, USA. The mineral lease comprises 200 acres and includes both the surface as well as the mineral rights over the historic Bama Mine.
Click Here
Alabama Graphite Reports Higher Grade, Near Surface (oxidized zone) Intercepts within New Geophysical Targets at its Coosa Project, Alabama, USA
Vancouver, BC / TNW-ACCESSWIRE / September 16, 2014 / Alabama Graphite Corp. (the “Company”) (TSX-V:ALP) (OTCQX:ABGPF) (FRANKFURT: 1AG WKN: A1J35M) (ISIN# CA0102931080) is pleased to report assay results from the summer 2014 sonic drilling program at its Coosa Graphite Project in Alabama, USA. Sonic drilling was chosen because of its ability to drill on established roads without extensive pad preparation as well as accommodating the Company’s desire to economically and preferentially test only the upper oxidized portions (0-65ft depth) of individual targets identified by the airborne survey completed in May, 2014.
iWallet Names Jack Chadsey CEO; Secure Luxury Techcessories Maker Appoints Retail Veteran to Top Post
iWallet Corporation (OTCQB: IWAL), the secure luxury techcessories company, has named Jack Chadsey as its new CEO.
Chadsey replaces Steve Cabouli, who will continue to serve as President and a member of the Board of Directors.
Chadsey’s retail career includes senior executive positions with premier retailers, including May Department Stores Company, Kohl’s, Dayton Hudson, Target and Sunglass Hut International where as President and CEO, he led the company through an IPO and a major international expansion strategy. Since leaving Sunglass Hut, Chadsey has been involved in the private retail sector providing equity capital, board representation and operating management expertise to specialty retailers.
The iWallet expects to usher in a new generation of smart techcessories that leverage the latest technology, such as a biometric fingerprint readers, to not only act as a vault to protect cash, credit cards and personal information, but also as a fashion statement. A registered trademark in the United States for wallets and wallets connected to smartphones, with worldwide patents, iWallet is focused on the design and development of physical, yet innovative personal, luxury security products that incorporate the latest security and communication technologies to protect against identity, personal and financial information theft.
Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals
MISSISSAUGA, ON, Sept. 8, 2014 /CNW/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has reached a full settlement with Mallinckrodt Inc. of Nuvo’s claims and Mallinckrodt’s counterclaim relating to Nuvo’s license to Mallinckrodt of the right to market and sell Pennsaid® and Pennsaid 2% in the United States. Under the terms of the settlement agreement,Mallinckrodt will return all U.S. rights to Pennsaid and Pennsaid 2% to Nuvo after a brief transition period and payUS$10 million.
Nuvo Research® Completes Enrolment in WF10™ Phase 2 Clinical Trial
MISSISSAUGA, ON, Sept. 3, 2014 /CNW/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has completed enrolment in its Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. The Company expects the trial to be completed in late 2014 with top-line results anticipated in the first quarter of 2015.